Who are H.P. ACTHAR SUBCUTANEOUS GEL INJECTION's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/h-p-acthar-subcutaneous-gel-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

H.P. ACTHAR SUBCUTANEOUS GEL INJECTION — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

H.P. ACTHAR SUBCUTANEOUS GEL INJECTION (H.P. ACTHAR SUBCUTANEOUS GEL INJECTION) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticotropin (ACTH) analog. Area: Immunology / Rheumatology / Ophthalmology.

marketed Corticotropin (ACTH) analog Melanocortin receptors (primarily MC2R on adrenal cortex; also MC1R, MC3R, MC4R, MC5R on immune cells) Immunology / Rheumatology / Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

H.P. ACTHAR SUBCUTANEOUS GEL INJECTION (H.P. ACTHAR SUBCUTANEOUS GEL INJECTION) — Tampa Bay Uveitis Center, LLC. H.P. Acthar is a corticotropin (ACTH) analog that stimulates the adrenal cortex to produce endogenous corticosteroids and has direct immunomodulatory effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION TARGET	H.P. ACTHAR SUBCUTANEOUS GEL INJECTION	Tampa Bay Uveitis Center, LLC	marketed	Corticotropin (ACTH) analog	Melanocortin receptors (primarily MC2R on adrenal cortex; also MC1R, MC3R, MC4R, MC5R on immune cells)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticotropin (ACTH) analog class)

Tampa Bay Uveitis Center, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). H.P. ACTHAR SUBCUTANEOUS GEL INJECTION — Competitive Intelligence Brief. https://druglandscape.com/ci/h-p-acthar-subcutaneous-gel-injection. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab